

DAFTAR PUSTAKA

1. Maidhof W, Hilas O. Lupus: An Overview of the Disease and Management Options. *Pharm Ther a peer-reviewed J Formul Manag*. 2012;37(4):240–9.
2. Weiss JE. Pediatric Systemic Lupus Erythematosus: More Than a Positive Antinuclear Antibody. *Pediatr Rev*. 2012;33(2):62–74.
3. Pons-Estel GJ, Alarcon G, Scofield L, Reinlib L, Cooper G. Understanding the Epidemiology and Progression of Systemic Lupus Erythematosus. *Semin Arthritis Rheum*. 2010;39(4):1–22.
4. Yusuf, Satria CDe, Sumadiono. Characteristics and outcomes of children with systemic lupus erythematosus at Dr. Sardjito hospital, Yogyakarta. 2015.
5. Kamphuis S, Silverman ED. Prevalence and burden of pediatric-onset systemic lupus erythematosus. *Nat Rev Rheumatol*. 2010;6(9):538–46.
6. Hiraki LT, Benseler SM, Tyrrell PN, Harvey E, Hebert D, Silverman ED. Ethnic differences in pediatric systemic lupus erythematosus. *J Rheumatol*. 2009;36(11):2539–46.
7. Mina R. Response to Therapy , Damage Accrual Compared to Adult. 2011;36(1):53–80.
8. Farkhati MY, Hapsara S, Satria CD. Antibodi Anti DS-DNA Sebagai Faktor Prognosis Mortalitas pada Lupus Eritematosus Sistemik. *Sari Pediatr*. 2012;14(2):2–8.
9. Anić F, Žuvić-Butorac M, Štimac D, Novak S. New classification criteria for systemic lupus erythematosus correlate with disease activity. *Croat Med J* . 2014;55(5):514–9.
10. Karuniawaty T, Sumadiono, Satria CD. Perbandingan Diagnosis Systemic Lupus Erythematosus Menggunakan Kriteria American College of Rheumatologi dan Systemic Lupus International Collaborating Clinics. *Sari Pediatr*. 2016;18(4):299–303.
11. Ippolito A, Petri M. An update on mortality in systemic lupus erythematosus. *Clin Exp Rheumatol*. 2008;26(51):872–9.



12. Hendler JV, de Souza L, de Freitas Zernow DC, Guimarães J, Bertotto T, Saldanha CF, et al. Survival analysis of patients with systemic lupus erythematosus in a tertiary hospital in southern Brazil. *Clin Rheumatol*. 2017;36(9):2005–10.
13. Setyadi A, Hermawan K. Factors contributing to mortality of patients with lupus nephritis Agus. 2015.
14. Urowitz M, Gladman D. Measures Of disease activity and damage in SLE. *Balliere's Clin Rheumatol*. 1998;12(3):3–11.
15. Hochberg MC, Perlmuter DL, Medsger TA, Steen V, Weisman MH, White B, et al. Prevalence of self-reported physician-diagnosed systemic lupus erythematosus in the USA. *Lupus*. 1995;4(6):454–6.
16. Arbuckle MR, McClain MT, Rubertone M V., Scofield RH, Dennis GJ, James JA, et al. Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus. *N Engl J Med*. 2003;349(16):1526–33.
17. Quintero-Del-Rio AI, Kelly JA, Kilpatrick J, James JA, Harley JB. The genetics of systemic lupus erythematosus stratified by renal disease: Linkage at 10q22.3 (SLEN1), 2q34-35 (SLEN2), and 11p15.6 (SLEN3). *Genes Immun*. 2002;3:S57–62.
18. Ptacek T, Li X, Kelley JM, Edberg JC. Copy number variants in genetic susceptibility and severity of systemic lupus erythematosus. *Cytogenet Genome Res*. 2009;123(1–4):142–7.
19. Mok C, Lau C. Pathogenesis of systemic lupus erythematosus. *Clin Pathol*. 2003;56:481–90.
20. Bertsias GK, Salmon JE, Boumpas DT. Therapeutic opportunities in systemic lupus erythematosus: State of the art and prospects for the new decade. *Ann Rheum Dis*. 2010;69(9):1603–11.
21. Hanly JG, Su L, Urowitz MB, Romero-diaz J, Gordon C, Bae S, et al. A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. *Arthritis Rheumatol*. 2016;68(8):1932–44.



22. Gutiérrez-Suárez R, Ruperto N, Gastaldi R, Pistorio A, Felici E, Burgos-Vargas R, et al. A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. *Arthritis Rheum.* 2006;54(9):2989–96.
23. Ormsby K. Pediatric Systemic Lupus Nephritis: Current Research in Treatment and Outcomes [Internet]. Thesis (M.Nurs.), College of Nursing, Washington State University. 2012. p. 1–54.
24. Knight JS, Kaplan MJ. Cardiovascular disease in lupus: Insights and updates. *Curr Opin Rheumatol.* 2013;25(5):597–605.
25. Zeller CB, Appenzeller S. Cardiovascular disease in systemic lupus erythematosus: the role of traditional and lupus related risk factors [review]. *Curr Cardiol Rev.* 2008;4(2):116–22.
26. Kakati S, Barman B, Ahmed SU, Hussain M. Neurological manifestations in systemic lupus erythematosus: A single centre study from north east India. *J Clin Diagnostic Res.* 2017;11(1):05–9.
27. Giannouli S, Voulgarelis M, Ziakas PD, Tzioufas AG. Anaemia in systemic lupus erythematosus: From pathophysiology to clinical assessment. *Ann Rheum Dis.* 2006;65(2):144–8.
28. Carmier D, Marchand-Adam S, Diot P, Diot E. Respiratory involvement in systemic lupus erythematosus. *Rev Mal Respir [Internet].* 2010;27(8):66–78.
29. Wichainun R, Kasitanon N, Wangkaew S, Hongsongkiet S, Sukitawut W, Louthrenoo W. Sensitivity and specificity of ANA and anti-dsDNA in the diagnosis of systemic lupus erythematosus: A comparison using control sera obtained from healthy individuals and patients with multiple medical problems. *Asian Pacific J Allergy Immunol.* 2013;31(4):292–8.



30. Costenbader KH, Desai A, Alarcon G, Hiraki LT, Shaykevich T, Brookhart A, et al. Trends in the Incidence, Demographics and Outcomes of End-Stage Renal Disease Due to Lupus Nephritis in the U.S.,1995-2006. *Arthritis Rheumatol.* 2011;63(6):1681–8.
31. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. *Arthritis Care Res.* 2012;64(6):797–808.
32. Lech M, Anders H-J. The Pathogenesis of Lupus Nephritis. *J Am Soc Nephrol [Internet]*. 2013;24(9):1357–66.
33. Hanly JG, O’Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, et al. The frequency and outcome of lupus nephritis: Results from an international inception cohort study. *Rheumatol (United Kingdom)*. 2015;55(2):252–62.
34. Haładyj E, Cervera R. Do we still need renal biopsy in lupus nephritis? *Reumatologia*. 2016;54(2):61–6.
35. Bomback AS, Appel GB. Updates on the Treatment of Lupus Nephritis. *J Am Soc Nephrol [Internet]*. 2010;21(12):2028–35.
36. Kasjmir YI, Handono K, Wijaya LK, Hamijoyo L, Albar Z, Kalim H, et al. Diagnosis dan Pengelolaan Lupus Eritematosus Sistemik. Rekomendasi Perhimpunan Reumatologi Indonesia. 2011. p. 1–54.
37. Mina R, Scheven E, Ardoin S, Eberhard A, Punaro M, Ilowite N, et al. Consensus Treatment Plans for Induction Therapy of Newly-diagnosed Proliferative Lupus Nephritis in Juvenile Systemic Lupus Erythematous. *Arthritis Care Res.* 2012;64(3):375–83.
38. Demircin G. An Update on Treatment and Outcome of Lupus Nephritis in Children. *Ann Pediatr Rheumatol.* 2013;2(5):99–106.
39. Richey M. The management of lupus nephritis. In: Lippincott Williams & Wilkins. 2014. p. 1–6.



40. Jones K, Banerjee J, Boddy S-A, Grier D, Jadresic L, Tullus K, et al. Urinary tract infection in children: diagnosis and treatment. In: Royal College of Obstetricians and Gynaecologist [Internet]. 2007. p. 1–126.
41. Sudung O. Pardede, Taralan Tambunan, Husein Alatas, Partinin Pudjiastuti Trihono ELH. Konsensus Infeksi Saluran Kemih Pada Anak. In: Ikatan Dokter Anak Indonesia (IDAI) Unit Kerja Koordinasi (UKK) Nefrologi. 2011. p. 1–30.
42. White B. Diagnosis and treatment of urinary tract infections. *Am Acad Fam Physicians*. 2011;83(4):409–15.
43. Tsai YC, Hou CL, Yao TC, Chen LC, Jaing TH, Huang JL. Risk factors and bacterial profiles of urinary tract infections in patients with systemic lupus erythematosus. *Asian Pacific J Allergy Immunol*. 2007;25(2–3):155–61.
44. Bosch X, Guilabert A, Pallarés L, Cervera R, Ramos-Casals M, Bové A, et al. Infections in systemic lupus erythematosus: A prospective and controlled study of 110 patients. *Lupus*. 2006;15(9):584–9.
45. Lee PPW, Lee TL, Ho MHK, Wong WHS, Lau YL. Recurrent major infections in juvenile-onset systemic lupus erythematosus - A close link with long-term disease damage. *Rheumatology*. 2007;46(8):1290–6.
46. Jung JY, Suh CH. Infection in systemic lupus erythematosus, similarities, and differences with lupus flare. *Korean J Intern Med*. 2017;32(3):429–38.
47. Skare TL, Dagostini JS, Zanardi PI, Nisihara R. Infections and Systemic Lupus Erythematosus. *Einstein J Biol Med*. 2016;14(1):47–51.
48. Sivaraj, Durrani, Denniston, Murray, Gordon C. Ocular manifestations of systemic lupus erythematosus. *J Rheumatol*. 2007;46:1757–62.
49. Ponticelli C, Moroni G. Flares in lupus nephritis: Incidence, impact on renal survival and management. *Lupus*. 1998;7(9):635–8.



50. Chen YE, Korbort SM, Katz RS, Schwartz MM, Lewis EJ, Roberts JL, et al. Value of a complete or partial remission in severe lupus nephritis. *Clin J Am Soc Nephrol*. 2008;3(1):46–53.
51. Touma Z. Derivation of an Appropriate Outcome Measure in Lupus. In: Wallace DJ, editor. *Dubois Lupus Erythematosus*. 8th ed. 2012. p. 1–140.
52. Lam G, Petri M. Assessment of systemic lupus erythematosus. *Clin Exp Rheumatol*. 2005;23(39):120–32.
53. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The Development and Initial Validation of The Systemic Lupus International Collaborating Clinics/ American College of Rheumatology Damage Index For Systemic Lupus Erythematosus. Vol. 39, *Arthritis and Rheumatism*. 1996. p. 363–9.
54. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients. *Medicine (Baltimore)*. 2003;82(5):299–308.
55. Bernatsky S, Ramsey-goldman R, Labrecque J, Joseph L, Boivin J, Petri M, et al. Cancer risk in systemic lupus: An updated international multi-centre cohort study. *Autoimmun J*. 2013;23:130–5.
56. Klack K, Bonfa E, Neto EFB. Diet and nutritional aspects in systemic lupus erythematosus. *Rev Bras Reumatol*. 2012;52(3):384–408.
57. Aparicio-Soto M, Sánchez-Hidalgo M, Alarcón-De-La-Lastra C. An update on diet and nutritional factors in systemic lupus erythematosus management. *Nutr Res Rev*. 2017;30(1):118–37.
58. Borges MC, dos Santos F de MM, Telles RW, Lanna CCD, Correia MITD. Nutritional status and food intake in patients with systemic lupus erythematosus. *Nutrition*. 2012;28(11–12):1098–103.



59. McElhone K, Abbott J, Gray J, Williams A, Teh LS. Patient perspective of systemic lupus erythematosus in relation to health-related quality of life concepts: A qualitative study. *Lupus*. 2010;19(14):1640–7.
60. Olesińska M, Saletra A. Quality of life in systemic lupus erythematosus and its measurement. *Reumatologia*. 2018;56(1):45–54.
61. Kulczycka L, Sysa-Jędrzejowska A, Robak E. Quality of life and satisfaction with life in SLE patients-the importance of clinical manifestations. *Clin Rheumatol*. 2010;29(9):991–7.
62. Liang MH, Schur PH, Fortin P, St.Clair EW, Balow JE, Costenbader K, et al. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. *Arthritis Rheum*. 2006;54(2):421–32.
63. Mosca, M Bombardieri S. Assessing remission in systemic lupus erythematosus. *Clin Exp Rheumatol Rheumatol*. 2006;24(Suppl. 43):100–4.
64. Varma P, Subba M, Madhoosudanan. Cyclophosphamide Induced Haemorrhagic Cystitis. Vol. 54, *Medical Journal Armed Forces India*. Elsevier B.V. on behalf of Director General, Armed Forces Medical Services; 1998. p. 59–60.
65. Heffner VA, Gorelick MH. Pediatric Urinary Tract Infection. *Clin Pediatr Emerg Med*. 2008;9(4):233–7.
66. Shoughy SS, Tabbara KF. Ocular findings in systemic lupus erythematosus. *Saudi J Ophthalmol*. 2016;30(2):117–21.
67. De Rossi SS, Glick M. Lupus erythematosus: Considerations for dentistry. *J Am Dent Assoc*. 1998;129(3):330–9.
68. Al-Mutairi KD, Al-Zahrani MS, Bahlas SM, Kayal RA, Zawawi KH. Periodontal findings in systemic lupus erythematosus patients and healthy controls. *Saudi Med J*. 2015;36(4):463–8.



69. Hammoudeh M, Al-Momani A, Sarakbi H, Chandra P, Hammoudeh S. Oral Manifestations of Systemic Lupus Erythematosus Patients in Qatar: A Pilot Study. *Int J Rheumatol*. 2018;2018:1–6.
70. Bruce IN, O’Keeffe AG, Farewell V, Hanly JG, Manzi S, Su L, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. *Ann Rheum Dis*. 2015;74(9):1706–13.
71. Park DJ, Kang JH, Lee JW, Lee KE, Kim TJ, Park YW, et al. Risk factors to predict the development of chronic kidney disease in patients with lupus nephritis. *Lupus*. 2017;26(11):1139–48.
72. Pardede SO, Chunnaedy S. Penyakit Ginjal Kronik pada Anak. *Sari Pediatr*. 2009;11(3):199–203.
73. Rygg M, Pistorio A, Ravelli A, Maghnie M, Iorgi N Di, Bader-Meunier B, et al. A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus. *Ann Rheum Dis*. 2012;71(4):511–7.
74. Eriksson K, Svenungsson E, Karreskog H, Gunnarsson I, Gustafsson J, Möller S, et al. Physical activity in patients with systemic lupus erythematosus and matched controls. *Scand J Rheumatol*. 2012;41(4):290–7.
75. Mok CC. Con: Cyclophosphamide for the treatment of lupus nephritis. *Nephrol Dial Transplant*. 2016;31(7):1053–7.
76. Sigdel MR, Kafle MP, Shah DS. Outcome of low dose cyclophosphamide for induction phase treatment of lupus nephritis, a single center study. *BMC Nephrol*. 2016;17(1):1–7.
77. Dan D, Fischer R, Adler S, Förger F, Villiger PM. Cyclophosphamide: As bad as its reputation?: Long-term single centre experience of cyclophosphamide side effects in the treatment of systemic autoimmune diseases. *Swiss Med Wkly*. 2015;144(October):1–7.



78. Hopkins RL, Leinung MC. Exogenous Cushing's syndrome and glucocorticoid withdrawal. *Endocrinol Metab Clin North Am.* 2005;34(2):371–84.
79. Wang M. The role of glucocorticoid action in the pathophysiology of the Metabolic Syndrome. *Nutr Metab.* 2005;2:1–14.
80. García-Carrasco M, Mendoza-Pinto C, Escárcega R, Jiménez-Hernández M, Etchegaray Morales I, Munguía Realpozo P, et al. Osteoporosis in patients with systemic lupus erythematosus. *Imaj.* 2009;11(8):486–91.
81. Phulke S, Kaushik S, Kaur S, Pandav SS. Steroid-induced Glaucoma: An avoidable irreversible blindness. *J Curr Glaucoma Pract.* 2017;11(2):67–72.
82. Abdalla E, Jeyaseelan L, Ullah I, Abdwani R. Growth pattern in children with systemic lupus erythematosus. *Oman Med J.* 2017;32(4):284–90.
83. Goodwin JE, Geller DS. Glucocorticoid-induced hypertension. *Pediatr Nephrol.* 2012;27(7):1059–66.
84. Goleva E, Covar R, Martin R, Leung D. Corticosteroid pharmacokinetic abnormalities in overweight and obese corticosteroid resistant asthmatics. *Allergy Clin Immunol Pr.* 2015;155(9):1683–95.
85. Pons-Estel GJ, Alarcón GS, McGwin G, Danila MI, Zhang J, Bastian HM, et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: data from a multiethnic US cohort. *Arthritis Care Res.* 2009;61(6):830–9.
86. Hansen MF, Schuman S, Scott I, Fekrat S, Marmor M. Hydroxychloroquine-Induced Retinal Toxicity. *Ophtalmic pearls.* 2011;33–5.
87. Malcangi G, Fraticelli P, Palmieri C, Cappelli M, Danieli MG. Hydroxychloroquine-induced seizure in a patient with systemic lupus erythematosus. *Rheumatol Int.* 2000;20(1):31–3.
88. Kwon JB, Kleiner A, Ishida K, Godown J, Ciafaloni E, Looney RJ. Hydroxychloroquine-induced myopathy. *J Clin Rheumatol.* 2010;16(1):28–31.



89. Rezaieyazdi Z, Tavakoli T, Khajehdaluae M, Honarmand S. Efficacy of long-term maintenance therapy with mycophenolate mofetil in lupus nephritis. Springerplus. 2014;3(1):638.
90. Kanda H, Kubo K, Tateishi S, Sato K, Yonezumi A, Yamamoto K, et al. Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy. Lupus. 2005;14:288–92.
91. Fernandes M, Vara R, Isenberg D. Assesment of long-term remission in lupus nephritis patients: a retrospective analysis over 30 years. Rheumatology.2015;54:1403-07
92. Fernandez D, Kirou K. What Causes Lupus Flare?. Curr Rheumatol.2016;18:2-10
93. Moroni G, Quaglini S, Maccario M, Banvi G, Ponticelli G. Nephritic flares are predictor of bad long-term renal outcome in lupus nephritis. Kidney International.1996;50:2047-53.
94. Chambers S, Isenberg D, Rahman A. Treatment adherence and clinical outcome in systemic lupus erythematosus . Rheumatology. 2007;46:895-898.
95. Edwards C.J, Lian Y, Badsha H, The C, Arden N, Chng H. Hospitalization of individuals with systemic lupus erythematosus: characteristics and predictors of outcome. Lupus. 2003;12: 672-76.